Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoline SCHEMBL29360339 | 0.87 | — | — | |
| Indoline SCHEMBL5629 | 0.87 | — | — | |
| Indoline SCHEMBL27584027 | 0.85 | HTR2C (0.46) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL4685686 | 0.85 | DRD2 (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL11570171 | 0.85 | HTR2C (0.46) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL23295083 | 0.85 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL11401846 | 0.85 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL1587228 | 0.85 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL8194348 | 0.85 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL10723456 | 0.85 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5301469-B2 | — | — | 2013-09-25 | — | — | JP | disclosed |
| EP-2114877-B1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| CN-101622230-B | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists | MERCK FROSST CANADA LTD CA | 2012-08-22 | — | — | CN | disclosed |
| CN-101622230-B | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists | MERCK FROSST CANADA LTD CA | 2012-08-22 | — | — | CN | disclosed |
| CN-101622230-B | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists | MERCK FROSST CANADA LTD CA | 2012-08-22 | — | — | CN | disclosed |
| US-8158671-B2 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK CANADA INC. (CA) | 2012-04-17 | — | — | US | disclosed |
| US-8158671-B2 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK CANADA INC. (CA) | 2012-04-17 | — | — | US | disclosed |
| US-8158671-B2 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK CANADA INC. (CA) | 2012-04-17 | — | — | US | disclosed |
| WO-2010121382-A1 | PROCESS FOR MAKING INDOLE CYCLOPROPYL AMIDE DERIVATIVES | MERCK FROSST CANADA LTD. (CA) | 2010-10-28 | — | — | WO | disclosed |
| CN-101622230-A | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD | 2010-01-06 | — | — | CN | disclosed |
| CN-101622230-A | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD | 2010-01-06 | — | — | CN | disclosed |
| CN-101622230-A | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD | 2010-01-06 | — | — | CN | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| EP-2114877-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114877-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | PLAU 4321/4885SMYD3 4020/4885HTR2C 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.